However, in type 2 endometrial cancer, 65 (79.5%) or 67 (81.7%) premenopausal patients were ER or PR positive, which was significantly higher than that in postmenopausal patients (53.5% were ER positive or 58.5% were PR positive) (Table 4, p = 0.0001 or p = 0.0004). The gene discussed is ESR1; the disease is endometrial cancer.